vs
柯达（KODK）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
柯达的季度营收约是Ultragenyx Pharmaceutical Inc.的1.4倍（$290.0M vs $207.3M），柯达净利率更高（-37.2% vs -62.0%，领先24.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 9.0%），柯达自由现金流更多（$483.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 7.9%）
伊士曼柯达公司，常简称为柯达，是一家源自美国的知名影像企业，总部位于纽约州罗切斯特，注册于新泽西州。柯达在摄影胶片领域拥有悠久的历史，曾率先将摄影胶片产品推向大众市场，如今仍围绕传统胶片影像业务开发各类相关产品。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
KODK vs RARE — 直观对比
营收规模更大
KODK
是对方的1.4倍
$207.3M
营收增速更快
RARE
高出16.9%
9.0%
净利率更高
KODK
高出24.8%
-62.0%
自由现金流更多
KODK
多$583.8M
$-100.8M
两年增速更快
RARE
近两年复合增速
7.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $290.0M | $207.3M |
| 净利润 | $-108.0M | $-128.6M |
| 毛利率 | 23.1% | — |
| 营业利润率 | -0.3% | -54.7% |
| 净利率 | -37.2% | -62.0% |
| 营收同比 | 9.0% | 25.9% |
| 净利润同比 | -515.4% | 3.5% |
| 每股收益（稀释后） | $-1.22 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KODKRARE
| Q4 25 | $290.0M | $207.3M | ||
| Q3 25 | $269.0M | $159.9M | ||
| Q2 25 | $263.0M | $166.5M | ||
| Q1 25 | $247.0M | $139.3M | ||
| Q4 24 | $266.0M | $164.6M | ||
| Q3 24 | $261.0M | $139.5M | ||
| Q2 24 | $267.0M | $147.0M | ||
| Q1 24 | $249.0M | $108.8M |
净利润KODKRARE
| Q4 25 | $-108.0M | $-128.6M | ||
| Q3 25 | $13.0M | $-180.4M | ||
| Q2 25 | $-26.0M | $-115.0M | ||
| Q1 25 | $-7.0M | $-151.1M | ||
| Q4 24 | $26.0M | $-133.2M | ||
| Q3 24 | $18.0M | $-133.5M | ||
| Q2 24 | $26.0M | $-131.6M | ||
| Q1 24 | $32.0M | $-170.7M |
毛利率KODKRARE
| Q4 25 | 23.1% | — | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 19.4% | — | ||
| Q1 25 | 18.6% | — | ||
| Q4 24 | 19.2% | — | ||
| Q3 24 | 17.2% | — | ||
| Q2 24 | 21.7% | — | ||
| Q1 24 | 19.7% | — |
营业利润率KODKRARE
| Q4 25 | -0.3% | -54.7% | ||
| Q3 25 | 7.1% | -106.9% | ||
| Q2 25 | -1.9% | -64.8% | ||
| Q1 25 | -5.3% | -102.6% | ||
| Q4 24 | -3.0% | -74.3% | ||
| Q3 24 | -3.1% | -94.6% | ||
| Q2 24 | 0.7% | -79.1% | ||
| Q1 24 | 2.8% | -151.9% |
净利率KODKRARE
| Q4 25 | -37.2% | -62.0% | ||
| Q3 25 | 4.8% | -112.8% | ||
| Q2 25 | -9.9% | -69.0% | ||
| Q1 25 | -2.8% | -108.5% | ||
| Q4 24 | 9.8% | -80.9% | ||
| Q3 24 | 6.9% | -95.7% | ||
| Q2 24 | 9.7% | -89.5% | ||
| Q1 24 | 12.9% | -156.8% |
每股收益（稀释后）KODKRARE
| Q4 25 | $-1.22 | $-1.28 | ||
| Q3 25 | $-0.08 | $-1.81 | ||
| Q2 25 | $-0.36 | $-1.17 | ||
| Q1 25 | $-0.12 | $-1.57 | ||
| Q4 24 | $0.22 | $-1.34 | ||
| Q3 24 | $0.15 | $-1.40 | ||
| Q2 24 | $0.23 | $-1.52 | ||
| Q1 24 | $0.30 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $436.0M | $421.0M |
| 总债务越低越好 | $209.0M | — |
| 股东权益账面价值 | $614.0M | $-80.0M |
| 总资产 | $1.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资KODKRARE
| Q4 25 | $436.0M | $421.0M | ||
| Q3 25 | $168.0M | $202.5M | ||
| Q2 25 | $155.0M | $176.3M | ||
| Q1 25 | $158.0M | $127.1M | ||
| Q4 24 | $201.0M | $174.0M | ||
| Q3 24 | $214.0M | $150.6M | ||
| Q2 24 | $251.0M | $480.7M | ||
| Q1 24 | $262.0M | $112.3M |
总债务KODKRARE
| Q4 25 | $209.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $467.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益KODKRARE
| Q4 25 | $614.0M | $-80.0M | ||
| Q3 25 | $762.0M | $9.2M | ||
| Q2 25 | $528.0M | $151.3M | ||
| Q1 25 | $563.0M | $144.2M | ||
| Q4 24 | $641.0M | $255.0M | ||
| Q3 24 | $982.0M | $346.8M | ||
| Q2 24 | $961.0M | $432.4M | ||
| Q1 24 | $951.0M | $140.3M |
总资产KODKRARE
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $1.9B | $1.3B | ||
| Q1 25 | $1.9B | $1.3B | ||
| Q4 24 | $2.0B | $1.5B | ||
| Q3 24 | $2.4B | $1.5B | ||
| Q2 24 | $2.4B | $1.6B | ||
| Q1 24 | $2.3B | $1.3B |
负债/权益比KODKRARE
| Q4 25 | 0.34× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.73× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $489.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $483.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 166.6% | -48.6% |
| 资本支出强度资本支出/营收 | 2.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $446.0M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流KODKRARE
| Q4 25 | $489.0M | $-99.8M | ||
| Q3 25 | $21.0M | $-91.4M | ||
| Q2 25 | $8.0M | $-108.3M | ||
| Q1 25 | $-38.0M | $-166.5M | ||
| Q4 24 | $4.0M | $-79.3M | ||
| Q3 24 | $-21.0M | $-67.0M | ||
| Q2 24 | $-7.0M | $-77.0M | ||
| Q1 24 | $17.0M | $-190.7M |
自由现金流KODKRARE
| Q4 25 | $483.0M | $-100.8M | ||
| Q3 25 | $17.0M | $-92.7M | ||
| Q2 25 | $-4.0M | $-110.7M | ||
| Q1 25 | $-50.0M | $-167.8M | ||
| Q4 24 | $-13.0M | $-79.5M | ||
| Q3 24 | $-41.0M | $-68.6M | ||
| Q2 24 | $-16.0M | $-79.0M | ||
| Q1 24 | $7.0M | $-193.9M |
自由现金流率KODKRARE
| Q4 25 | 166.6% | -48.6% | ||
| Q3 25 | 6.3% | -58.0% | ||
| Q2 25 | -1.5% | -66.5% | ||
| Q1 25 | -20.2% | -120.5% | ||
| Q4 24 | -4.9% | -48.3% | ||
| Q3 24 | -15.7% | -49.2% | ||
| Q2 24 | -6.0% | -53.7% | ||
| Q1 24 | 2.8% | -178.2% |
资本支出强度KODKRARE
| Q4 25 | 2.1% | 0.5% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 4.6% | 1.5% | ||
| Q1 25 | 4.9% | 1.0% | ||
| Q4 24 | 6.4% | 0.1% | ||
| Q3 24 | 7.7% | 1.2% | ||
| Q2 24 | 3.4% | 1.4% | ||
| Q1 24 | 4.0% | 3.0% |
现金转化率KODKRARE
| Q4 25 | — | — | ||
| Q3 25 | 1.62× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | -1.17× | — | ||
| Q2 24 | -0.27× | — | ||
| Q1 24 | 0.53× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KODK
| Segment Continuing Operations | $195.0M | 67% |
| Advanced Materials And Chemicals | $85.0M | 29% |
| Other | $7.0M | 2% |
| All Other | $3.0M | 1% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
